Obsidian Therapeutics Inc OBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
-
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
-
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Trading Information
- Previous Close Price
- $13.20
- Day Range
- $12.07–13.39
- 52-Week Range
- $12.07–49.97
- Bid/Ask
- $12.25 / $19.58
- Shares Outstanding
- 61.77M
- Market Cap
- $756.10M
- Volume/Avg
- 517,206 / 414,206
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.obsidiantx.com
Valuation
|
Metric
|
OBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OBX
|
|---|---|
Quick Ratio | 3.86 |
Current Ratio | 4.21 |
Interest Coverage | — |
Quick Ratio
OBX
Profitability
|
Metric
|
OBX
|
|---|---|
Return on Assets (Normalized) | −109.60% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
OBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Z%K$T! | LOCK|<WFQ! | $128B | |||
| Moderna Inc
MRNA
| LOCK|SClZ$N | LOCK|NX! | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|yVTMCFK | LOCK|@v#bf | $76B | |||
| argenx SE ADR
ARGX
| LOCK|HW#d@<? | LOCK|kS | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|MM!x@b | LOCK|@K | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|xgs$>F | LOCK|l?qf | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Pr^Pkc!w | LOCK|W<K^g | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|t@&xB# | LOCK|?% | $23B | |||
| Incyte Corp
INCY
| LOCK|S>Dky> | LOCK|c#l | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|kwfth? | LOCK|Y? | $14B |
United States